Home・Aktien・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Geschlossen

BrancheGesundheitswesen

20.67 -1.15

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.38

Max

21.72

Schlüsselkennzahlen
By Trading Economics
Einkommen	-24M -54M
Verkäufe	-2.5M 305M
EPS	0.32
Gewinnspanne	-17.851
Angestellte	3,100
EBITDA	-24M -32M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+121.12% upside

Dividenden
By Acuity
Nächstes Ergebnis	11. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-735M 4B
Vorheriger Eröffnungskurs	21.82
Vorheriger Schlusskurs	20.67

Nachrichtenstimmung

By Acuity

100%

323 / 340 Ranking in Healthcare

Legend Biotech Corp ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Aug. 2026, 23:16 UTC

Legend Biotech Corp. shares are higher in after-market hours, reflecting positive market conditions amid a Consumer Price Index report that met forecasts.

11. Aug. 2026, 23:46 UTC

Shares of Legend Biotech Corp are higher in after-market hours, maintaining a position above the 20-day moving average amid stable trading conditions.

10. Aug. 2026, 23:06 UTC

Shares of Legend Biotech are higher in after-market trading, settling above Monday's close despite mixed market sentiment and geopolitical tensions.

7. Aug. 2026, 23:46 UTC

Shares of Legend Biotech Corp traded higher in after-market hours, amid a broader market context of a declining unemployment rate.

6. Aug. 2026, 20:06 UTC

Legend Biotech Corp shares are higher today, reflecting a shift from recent trends. No specific company news was identified to explain this movement.

4. Aug. 2026, 19:36 UTC

Legend Biotech Corp shares are higher today, recovering from an earlier low. Positive momentum persists despite a decline in U.S. core factory orders.

3. Aug. 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31. Juli 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30. Juli 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29. Juli 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28. Juli 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27. Juli 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24. Juli 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22. Juli 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21. Juli 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20. Juli 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Peer-Vergleich

Kursveränderung

Legend Biotech Corp ADR Prognose

Kursziel

By TipRanks

121.12% Vorteil

12-Monats-Prognose

Durchschnitt 48.27 USD 121.12%

Hoch 80 USD

Tief 24 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Legend Biotech Corp ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Legend Biotech Corp ADR – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.